Guideline Recommendations for Rheumatoid Arthritis Management in Chronic Kidney Disease

Initial DMARD Strategy by CKD Stage

Start methotrexate 15 mg weekly as the first‑line disease‑modifying antirheumatic drug (DMARD) in patients with CKD stages 1‑3 (eGFR ≥ 30 mL/min/1.73 m²); reduce the dose as renal function declines and avoid methotrexate completely in CKD stages 4‑5 (eGFR < 30 mL/min/1.73 m²). 1
Begin methotrexate at 15 mg weekly together with folic‑acid supplementation as the anchor DMARD for all newly diagnosed rheumatoid arthritis patients, irrespective of serostatus. 1
Add low‑dose prednisone (≤ 7.5–10 mg/day) as a short‑term bridge therapy, tapering within 4–8 weeks to minimise long‑term toxicity. 1

Assess disease activity every 1–3 months using validated composite scores (SDAI, CDAI, or DAS28‑CRP) while the disease is active. 1
Aim for clinical remission (SDAI ≤ 3.3 or CDAI ≤ 2.8) as the primary therapeutic goal; low disease activity is an acceptable alternative. 5
If < 50 % improvement is not achieved by 3 months or the remission/low‑activity target is not reached by 6 months, escalate therapy immediately to prevent progressive joint damage. 3

When optimized methotrexate (20–25 mg/week, or maximum tolerated dose) fails, add triple therapy (hydroxychloroquine + sulfasalazine) or move to a biologic DMARD. 1
Preferred biologic options in combination with methotrexate include TNF inhibitors, IL‑6 inhibitors, or abatacept. 1

After failure of two TNF inhibitors, switch to a biologic with a different mechanism of action rather than cycling within the same class. 5

Do not use oral NSAIDs in CKD stages 4‑5 because of a high risk of acute kidney injury and accelerated renal disease progression. 6
In CKD stage 3, NSAIDs should be prescribed only after an individualized risk‑benefit assessment, preferably avoided; if required, co‑prescribe a proton‑pump inhibitor to lower gastrointestinal toxicity. 6

Limit glucocorticoid therapy to ≤ 6 months at doses ≤ 7.5–10 mg/day prednisone‑equivalent, with rapid tapering as clinically feasible. 1
Beyond 1–2 years, the cumulative risks of long‑term corticosteroid use (e.g., cataracts, osteoporosis, fractures, cardiovascular disease) outweigh the benefits. 7
If glucocorticoids are still needed after 2–3 months, this signals inadequate DMARD control and mandates escalation of disease‑modifying therapy. 4

Do not delay initiation of DMARD therapy, as postponement leads to irreversible joint damage that cannot be fully reversed later. 2
Avoid using NSAIDs or corticosteroids as monotherapy; they provide only symptomatic relief, do not modify disease, and can accelerate renal decline. 2
Do not underdose methotrexate in CKD stages 1‑3; the dose should be titrated up to 20–25 mg/week (or the maximum tolerated dose) before declaring treatment failure. 3